News @Gotham

May 21, 2019 - Gotham Therapeutics and ZoBio Achieve Significant Milestone in Epitranscriptomic Drug Discovery Collaboration

Gotham Therapeutics,and ZoBio announced significant progress made as part of their collaboration to identify therapeutic lead candidates for Gotham’s initial portfolio of epitranscriptomic targets. In the first project pursued within the collaboration, the initial phase for Gotham’s drug discovery project targeting the METTL3/METTL14 complex has been completed and a portfolio of small-molecule candidates will be further evaluated.



Gotham Therapeutics Strengthens Board of Directors and Scientific Advisory Board

In February 2019, Gotham Therapeutics announced the appointment of Carlo Incerti, M.D., Ph.D. as an independent Board Member. In addition, the company added Thomas Tuschl, Ph.D. as a Scientific Advisor.



Gotham Therapeutics Launches with $54 Million Series A

In October 2018, Gotham Therapeutics debuted with a $54 million Series A financing co-led by founding investor Versant Ventures, Forbion and S.R. One.


2nd Symposium on Nucleic Acid Modifications

Meet the team at the 2nd Symposium on Nucleic Acid Modifications “RNA modifications: Form, function and mechanism” at the Weizmann Institute of Science, Rehovot, Israel, June 25-27, 2019.



1st RNA Epigenetics in Human Disease Conference

Meet the team at the 1st RNA Epigenetics in Human Disease Conference at the St Catharine’s College, Cambridge, UK, September 17-20, 2019.


Stay In Touch! 

Gotham Therapeutics will be at the forefront of epitranscriptomics research and drug discovery. Staying in touch with us means staying up-to-date on the field.